Starlink Plans Satellite Orbit Reconfiguration in 2026 to Boost Space Safety 
Neuralink Plans Automated Brain Implant Surgeries and Mass Production by 2026 
Samsung Signals Comeback With HBM4 Chips as AI Market Heats Up 
Lockheed Martin Secures Nearly $500 Million in U.S. and Allied Defense Contracts 
Google Accelerates AI Infrastructure With Ironwood TPU Expansion in 2026 
Baidu Shares Surge as Company Plans Kunlunxin AI Chip Spin-Off and Hong Kong Listing 
Vanda Pharmaceuticals Wins FDA Approval for New Motion Sickness Drug After Four Decades 
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China as Competition Intensifies 
Anghami Stock Soars After Strong H1 2025 Results, Revenue Nearly Doubles on OSN+ Integration 
Nike Stock Rises After CEO Elliott Hill Buys $1 Million in Shares 
ByteDance Plans Massive AI Chip Spending Boost as Nvidia Demand Grows in China 
Applied Digital Stock Rises on AI Cloud Spinoff Plan and ChronoScale Launch 
Bain Capital Moves to Acquire Majority Stake in Echo Marketing 
Meta Acquires AI Startup Manus to Expand Advanced AI Capabilities Across Platforms 
Target Stock Rallies as Activist Interest Sparks Hopes for Strategic Change 
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China, Boosting Access to Wegovy and Mounjaro 
BURLINGAME, Calif., March 09, 2017 -- Corvus Pharmaceuticals, Inc. (Nasdaq:CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology therapies, today announced that the company will host and provide a live webcast for its R&D Day, starting at 9:00 AM ET on March 14, 2017 in New York City.
The event will highlight the emerging role of the adenosine axis in immuno-oncology and its potential to address the limitations of existing agents. Additionally, Corvus will provide updates on its progress in clinical trials evaluating its lead CPI-444 program as well as the company’s pipeline.
Speakers at the event include:
- Jonathan D. Powell, MD, PhD (Johns Hopkins University)
- Lawrence Fong, MD (University of California, San Francisco)
- Richard Miller, MD (Corvus Co-Founder, President and CEO)
| R&D Day Webcast and Conference Call Details | |||||
| Event Title: | R&D Day Update: The Emergence of the Adenosine Pathway in Cancer Immunotherapy | ||||
| Date: | Tuesday, March 14, 2017 | ||||
| Time: | 9:00 - 12:00 p.m. ET | ||||
| Webcast: | The live webcast and slide presentation can be accessed at https://event.webcasts.com/starthere.jsp?ei=1137880 | ||||
An archive of the webcast will be available in the Investors section of the company's website for 30 days following the event.
About Corvus Pharmaceuticals
Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development and commercialization of small molecule and antibody agents that target the immune system to treat patients with cancer. These agents block or modify crucial immune checkpoints and reprogram immune T-cells. Corvus’ lead product, CPI-444, is a checkpoint inhibitor that is designed to disable a tumor’s ability to subvert attack by the immune system by inhibiting adenosine in the tumor microenvironment. CPI-444 is a small molecule that is taken orally. CPI-444 is currently being evaluated in a multicenter Phase 1/1b clinical trial in patients with various solid tumors. This successive expansion cohort trial is examining the activity of CPI-444 both as a single agent and in combination with Genentech’s Tecentriq® (atezolizumab), an anti-PD-L1 antibody. Corvus is conducting the trial with Genentech, a member of the Roche Group, under a clinical trial collaboration the two companies entered into in October 2015. For more information, visit: www.corvuspharma.com.
Tecentriq® is a registered trademark of Genentech.
Corvus Contact: Jason Coloma SVP, Chief Business Officer Corvus Pharmaceuticals, Inc. +1-650-900-4511 [email protected] Media Contact: Julie Normart Pure Communications +1-415-946-1087 [email protected]
